低分割同期推量调强放疗联合贝伐珠单抗治疗脑胶质瘤的临床效果  

Clinical Effecte of Hypofractionated Simultaneous Boost Intensity-Modulated Radiotherapy Combined with Bevacizumab in the Treatment of Glioma

作　　者：范娟 杨东方 王森 王丽森 唐森 FAN Juan;YANG Dongfang;WANG Sen;WANG Lisen;TANG Sen(Department of Radiotherapy,Zhumadian Central Hospital,Zhumadian 463000,China;Department of Oncology,Zhumadian Central Hospital,Zhumadian 463000,China;Department of Neurology,Zhumadian Central Hospital,Zhumadian 463000,China)

机构地区：[1]驻马店市中心医院放疗科,河南驻马店463000 [2]驻马店市中心医院肿瘤内科,河南驻马店463000 [3]驻马店市中心医院神经内科,河南驻马店463000

出　　处：《河南医学研究》2023年第4期676-679,共4页Henan Medical Research

摘　　要：目的 探究低分割同期推量调强放疗与贝伐珠单抗联合治疗脑胶质瘤的临床效果。方法 选取2018年4月至2021年4月在驻马店市中心医院治疗的66例脑胶质瘤患者为研究对象,按随机数表法分为研究组33例、对照组33例。对照组治疗方式为低分割同期推量调强放疗,研究组治疗方式为低分割同期推量调强放疗与贝伐珠单抗联合,比较两组治疗后疗效、肿瘤标志物水平、不良反应与生存情况的差异。结果 研究组疗效与对照组相比更好,且疾病控制率、治疗有效率优于对照组(P<0.05)。治疗后,两组白细胞介素-2(IL-2)、IL-6、肿瘤坏死因子-α(TNF-α)、血管内皮生长因子(VEGF)、表皮生长因子(EGF)、免疫球蛋白(IgE)水平均降低,可溶性白细胞介素-2受体(SIL-2R)、多效生长因子(PTN)水平均升高;且研究组IL-2、IL-6、TNF-α、VEGF、EGF、IgE、SIL-2R、PTN水平均较对照组更低(P<0.05)。Kaplan-Meier生存分析显示,研究组总生存情况优于对照组(P<0.05)。结论 低分割同期推量调强放疗与贝伐珠单抗联合治疗脑胶质瘤疗效较好,可有效提高生存率。Objective To explore the clinical effects of hypofractionated simultaneous boost intensity modulated radiotherapy combined with bevacizumab in the treatment of glioma.Methods A total of 66 patients with glioma who were treated in Zhumadian Central Hospital from April 2018 to April 2021 were prospectively selected as the research objects, and they were divided into a study group of 33 cases and a control group of 33 cases according to the random number table method. The control group received hypofractionated simultaneous boost intensity-modulated radiotherapy, while the study group received hypofractionated simultaneous boosted intensity-modulated radiation therapy combined with bevacizumab. The efficacy, tumor marker levels, adverse effects and reactions were compared between the two groups after treatment. differences with survival.Results The curative effect of the study group was better than that of the control group, and the disease control rate and response rate were better than those of the control group(P<0.05). After treatment, the levels of interleukin 2(IL-2), IL-6, tumor necrosis factor-α(TNF-α), vascular endothelial growth factor(VEGF), endothelial growth factor(EGF), immunoglobulin E(IgE) in the two groups were decreased, while the levels of soluble interleukin-2 receptor(SIL-2R) and pleiotrophin(PTN) were increased. The levels of IL-2, IL-6, TNF-α, VEGF, EGF, IgE, SIL-2R, PTN were lower than those in the control group(P<0.05). Kaplan-Meier survival analysis showed that the overall survival of the study group was better than that of the control group(P<0.05).Conclusion Hypofractionated simultaneous boost intensity modulated radiotherapy combined with bevacizumab in the treatment of glioma has obvious curative effect and can effectively improve the survival rate.

关 键 词：脑胶质瘤 低分割 同期推量调强放疗 贝伐珠单抗 

分 类 号：R739.41[医药卫生—肿瘤]